We designed and prototyped an infusion pump for subcutaneous administration of immunoglobulin (IgG), an immunodeficiency treatment. The device is an improvement on the technology which is currently available. The prototype was fully functioning and was capable of administering customized medical therapy. This project was completed as the final project submission in University of Pennsylvania's Medical Devices (BE 470) course.
Video #1 - Preparing Immunotherapy Infusion Demo
Video #2 - Executing Immunotherapy Infusion Demo
Video #3 - Concluding Immunotherapy Infusion Demo
Video #4 - Syringe Purge Demo
Problem Statement
Patients with
compromised immune systems have what is called a primary immunodeficiency
disorder (PID), where part of the immune system such as the immunoglobulin (Ig),
or antibody population is missing or performing incorrectly. This makes them
more susceptible to severe and recurrent infections because their body defense
mechanism, the immune system, lacks a vital component (Bonagura) . As of 2007,
approximately “1 in 1,200 persons” is affected by PID in the United States (Boyle and Buckley) . Patients who are
unable to produce a sufficient amount of Ig require a treatment known as
immunoglobulin replacement therapy. By taking into account the advantages and
disadvantages of current treatments for PID, we propose a medical device that
performs as an antibody pump and can provide more constant delivery of
antibodies.
The current
standard of care offers monthly injections, via IV infusions, or weekly
subcutaneously-administered injections (Bonagura) .
The IV infusion is known as intravenous immunoglobulin (IVIG) therapy—it is
administered approximately every 28 days and is “effective in preventing
serious bacterial infections and improving the quality of life for treated
patients” (Kobrynski) .
The other method is subcutaneous (SCIG) treatment, which is different because
it is not administered through the vein and into the bloodstream, but rather
under the skin in fatty tissue of the thighs, upper arm, or abdomen. Other
differences include regularity of treatment reception, as SCIG must be
delivered weekly. We will focus only on IVIG.
Patients with
the immunodeficiency disorder are unable to produce the appropriate number of
antibodies that a healthy individual has and so this treatment seeks to provide
an external supply of antibodies on a regular basis. “Since [IgG] only replaces
the missing end product but does not correct the patient’s defect in antibody
production, [IgG] replacement is usually necessary for the patient’s lifetime” (Immunoglobulin Therapy & Other Medical Therapies
for Antibody Deficiencies) . This also creates a
peak and trough pattern for antibody levels (a graphic representation is
attached in the Figure 1). The peaks
arise when treatment is given at the beginning of the 28-cycle and there is a
trough in antibody levels towards the end of the cycle. Essentially, to prevent
a patient from having a below-normal level of antibodies, doctors prescribe a
large enough dose so that by the end of the month, patients will still have an
antibody count that is greater than or equal to approximately 800 mg/dL, the
healthy level for an adult (Immunoglobulins (IgG, IgA, and IgM), Serum) .
Figure 1 - Increasing regularity
of treatment decreases total amount of medication needed to maintain minimum,
healthy antibody levels for patients with Primary Immunodeficiency Disorder.
The areas under the curves decrease with greater regularity, which means less
medication required, and therefore lower costs.
This treatment
has been the standard of care because patients are able to go about their daily
normal lives, so long as they regularly receive infusion. However, the
treatment also has several disadvantages. IVIG therapy is extremely wasteful. Patients
must receive enough treatment such that the level of antibodies is sufficient until
each treatment This treatment must also continue for an indefinite amount of
time because it is not a curative process. The combination of these two issues
make costs extremely high for patients; the cost ranges from “$164 to $314” (Immune
Globulin Subcutaneous (Human), 20% Liquid) . Moreover, not only
are patients susceptible to lethargy when Ig levels are low but adverse effects
of IgG infusions also include “headache, myalgia, fever, chills, low back pain,
nausea and/or vomiting” (Duhem, Dicato and
Ries) .
As a result, patients require separate medications, both before and after
infusions to manage these side effects. The particular disadvantage we will
focus on is reducing costs for patients by increasing regularity of treatment
with the creation of a user-friendly infusion device.
The code for my project is attached here.
Device Specifications
This device is
essentially an infusion pump for immunodeficiency therapies. Patients will
receive medication through the pump. Patients typically know how much
medication they should receive from a doctor’s prescription, so they can simply
program that number through the keypad. This function will cause the motor to
move the carriage a certain distance back from its “home base” position. During
this time, the yellow LED will turn on to inform the patient that this function
is running. Then the patient will load the 60 mL syringe which will contain the
medication fluid. Once the patient initiates the infusion process and the motor
begins pushing the syringe forward, he/she can perform various functions for
important functions and information. For example, patients can navigate the
keypad to determine how much more time is remaining in the infusion, or they
can pause/cancel the infusion. When the infusion ends, the red LED turns on so
that the user can be aware that the overall procedure has ended.
Specification Table
Specification
|
Value,
Value Range, or Quality of Specification
|
Additional
Comments (if needed)
|
Battery Life of motor
|
Indefinite
|
Powered through outlet
|
Battery Life of LCD, LEDs, Arduino
|
Indefinite
|
Powered through computer
|
Syringe Life
|
Replace after each infusion
|
|
Tubing Life
|
Replace after each infusion
|
|
Needle Life
|
Replace after each infusion
|
|
Age requirements
|
Safe/intended for all ages
|
Doctor prescription required, but
operation should not be for children under
|
FDA Classification
|
Class II
|
Some harm to the user may occur because
of motor, tubing, and needle; mandatory performance standards required so
that users know that the medication works appropriately; other pumps are
given Class II regulatory controls
|
Sterility
|
Syringe, tubing, needle must be sterile
materials
|
Block Diagram
CAD Modeling
Feature and Benefit Table
Feature
|
Benefit
|
Red LED
|
Patient knows when infusion has
completed
|
Yellow LED
|
Patient knows when carriage is moving
to its appropriate place along rail
|
Green
|
Patient knows when…
|
LCD display
|
|
Servo Motor
|
|
Tubing
|
Wiring allows for simple transportation
of medication from the syringe to the patient
|
Needle
|
Transportation from the syringe to the
patient, as well
|
Arduino
|
Overall functionality and output device
controls
|
Prototype Description
The device we
have built is a user-friendly and easy to use apparatus at home. This allows
for increased regularity of treatment so that patients incur lower costs for
Primary Immunodeficiency Disorder therapies, which include antibody infusions. However,
our device has much room for improvement. To begin with, we would want our
device to mimic an insulin pump’s feature of checking blood insulin levels and
provide dosages appropriately; if our device could record patient antibody
levels, patients would receive more appropriate treatment, thereby further
decreasing costs and keeping patients healthier. For example, immune systems
may have to combat infections more actively during the winters when infections
are more prevalent. As a result, the daily dosage can be higher if a patient
needs it to be and lower when not necessary.
Other
improvements include changing the power system so that wiring is not necessary.
A battery-powered device would be more portable for the patient and allow for
less restricted movement. Additionally, our pump has an open design as of now,
but with more time, we would have placed it in a box so that the only parts of
the apparatus visible would be the LCD display and the rail for syringe
placement. Finally, we would improve the LCD functionality to include more
information such as the antibody level, calendar for treatments, and pre-set
settings for speeding up the infusion process and improving effectiveness of
the device.
PREVIOUS TECHNOLOGIES
PREVIOUS TECHNOLOGIES
CONCERNS
There are a wide range of treatment doses.
- how to accomodate all sizes
- http://emedicine.medscape.com/article/2157901-overview
Doctors may be comfortable with wastefulness
- Bloodwork does not directly identify the appropriate prescription level. It is hard to tell what is abnormal performance and what is low levels of antibodies.





